Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, et al. A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801. Int J Cancer 2024 Aug 14. doi: 10.1002/ijc.35116.
PMID: 39143041